Travere Therapeutics is focused on commercializing FILSPARI, a non-immunosuppressive therapy fully approved for treatment of IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company reported continued operating losses in Q2 2026 but maintains strong liquidity. Commercial execution in the U.S. remains critical as FILSPARI competes in a complex market with payer reimbursement challenges and generic competition to other products. Internationally, reliance on licensing partners limits direct control of growth outside the U.S. Regulatory compliance and litigation risks are persistent hurdles. Upcoming milestones include further market penetration of FILSPARI in FSGS and payer coverage expansion.